Solid Biosciences (SLDB) said it will provide a corporate update at the J.P. Morgan Healthcare Conference later Wednesday outlining its expanded clinical-stage pipeline and 2025 objectives.
Among the highlights from the presentation include its SGT-003 for Duchenne muscular dystrophy and SGT-212 for Friedreich's ataxia, Solid said. It said SGT-003 continued to be well tolerated in the first four patients dosed in an ongoing trial.
The company said it has resources to fund its key strategic priorities into 2026.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。